Scarica l'app Stockscreener
722.01
2.21%
15.60
Dopo l'orario di chiusura:
717.51
-4.50
-0.62%
Precedente Chiudi:
$706.41
Aprire:
$710.99
Volume 24 ore:
468.11K
Relative Volume:
1.20
Capitalizzazione di mercato:
$44.19B
Reddito:
$3.06B
Utile/perdita netta:
$1.28B
Rapporto P/E:
33.90
EPS:
21.2963
Flusso di cassa netto:
$447.35M
1 W Prestazione:
+1.98%
1M Prestazione:
+7.15%
6M Prestazione:
+15.97%
1 anno Prestazione:
+40.41%
Intervallo 1D:
$708.15
$723.28
Intervallo di 1 settimana:
$697.87
$723.28
Portata 52W:
$510.06
$723.28
Argen X Se Adr Stock (ARGX) Company Profile
Confronta ARGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
722.01 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-05-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Strong Buy |
| 2024-10-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-24 | Downgrade | UBS | Buy → Neutral |
| 2023-07-17 | Ripresa | Evercore ISI | Outperform |
| 2023-06-15 | Iniziato | Societe Generale | Sell |
| 2023-05-31 | Iniziato | UBS | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-14 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Iniziato | William Blair | Outperform |
| 2022-10-12 | Iniziato | Oppenheimer | Perform |
| 2022-07-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Ripresa | Stifel | Buy |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-23 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Iniziato | Deutsche Bank | Hold |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-18 | Iniziato | UBS | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Iniziato | Redburn | Neutral |
| 2021-03-05 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Iniziato | H.C. Wainwright | Neutral |
| 2020-02-10 | Iniziato | BofA/Merrill | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-10-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Iniziato | JP Morgan | Overweight |
| 2019-09-27 | Iniziato | Wells Fargo | Market Perform |
| 2019-09-16 | Ripresa | Cowen | Outperform |
| 2019-06-28 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-18 | Ripresa | SunTrust | Buy |
| 2019-01-04 | Iniziato | Morgan Stanley | Overweight |
| 2018-12-17 | Iniziato | Goldman | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-06-29 | Iniziato | Nomura | Buy |
| 2018-04-09 | Iniziato | SunTrust | Buy |
| 2018-01-29 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Argen X Se Adr Borsa (ARGX) Ultime notizie
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Stocks With Rising Composite Ratings: argenx ADR - MSN
Stocks With Rising Composite Ratings: Argenx ADR - inkl
Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily
Argenx: study met primary endpoint - AInvest
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewswire Inc.
Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com
Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.
This Stock Ran 31% In A Month. Will Upcoming News Revitalize It? - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl
Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa
Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria
argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com South Africa
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com
argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily
10 Stocks Analysts Are Upgrading Today - Insider Monkey
Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar
Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily
argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade - inkl
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa
Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily
Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India
Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India
Stifel maintains $780 target on argenx stock after FDA nod - Investing.com
Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily
Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa
Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com
Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com
TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India
TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa
Argen X Se Adr Azioni (ARGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.27%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):